Technical Analysis for IMUX - Immunic, Inc.

Grade Last Price % Change Price Change
grade F 7.88 3.28% 0.25
IMUX closed up 3.28 percent on Friday, November 15, 2019, on 73 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical IMUX trend table...

Date Alert Name Type % Chg
Hammer Candlestick Bullish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness 3.28%
BB Squeeze Ended Range Expansion 3.28%
Below Lower BB Weakness 3.28%
Down 3 Days in a Row Weakness 3.28%
Lower Bollinger Band Touch Weakness 3.28%
Oversold Stochastic Weakness 3.28%

Older signals for IMUX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Immunic, Inc. (Nasdaq:IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. Immunic's lead development program, IMU-838, is in phase 2 clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional phase 2 trial in Crohn's disease planned for 2019. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is planned to start at the Mayo Clinic.
Medicine Biopharmaceutical Medical Specialties Clinical Medicine Immunotherapy Autoimmune Diseases Multiple Sclerosis Psoriasis Ulcerative Colitis Abdominal Pain Crohn's Disease Relapsing Remitting Multiple Sclerosis Mayo Clinic
Is IMUX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 46.8
52 Week Low 6.0
Average Volume 21,756
200-Day Moving Average 11.5889
50-Day Moving Average 10.2284
20-Day Moving Average 8.427
10-Day Moving Average 8.2021
Average True Range 0.4638
ADX 38.14
+DI 10.2358
-DI 31.7331
Chandelier Exit (Long, 3 ATRs ) 7.908600000000001
Chandelier Exit (Short, 3 ATRs ) 8.9014
Upper Bollinger Band 9.1382
Lower Bollinger Band 7.7158
Percent B (%b) 0.12
BandWidth 16.879079
MACD Line -0.6008
MACD Signal Line -0.647
MACD Histogram 0.0462
Fundamentals Value
Market Cap 332.59 Million
Num Shares 42.2 Million
EPS -1.35
Price-to-Earnings (P/E) Ratio -5.84
Price-to-Sales 0.00
Price-to-Book 3.02
PEG Ratio -0.27
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.47
Resistance 3 (R3) 8.41 8.15 8.37
Resistance 2 (R2) 8.15 8.00 8.18 8.33
Resistance 1 (R1) 8.02 7.91 8.09 8.08 8.30
Pivot Point 7.76 7.76 7.80 7.79 7.76
Support 1 (S1) 7.63 7.61 7.70 7.69 7.46
Support 2 (S2) 7.37 7.52 7.40 7.43
Support 3 (S3) 7.24 7.37 7.39
Support 4 (S4) 7.30